1
|
Ishida H, Yamaguchi M, Saito SY, Furukawa T, Shannonhouse JL, Kim YS, Ishikawa T. Corrigendum to "Na(+)-dependent inactivation of vascular Na(+)/Ca(2+) exchanger responsible for reduced peripheral blood flow in neuropathic pain model" [Eur. J. Pharmacol. 910 (2021) 174448]. Eur J Pharmacol 2024; 970:176495. [PMID: 38490839 DOI: 10.1016/j.ejphar.2024.176495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2024]
Affiliation(s)
- H Ishida
- Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan; Department of Oral & Maxillofacial Surgery, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA
| | - M Yamaguchi
- Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan
| | - S Y Saito
- Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan; Faculty of Veterinary Medicine, Okayama University of Science, 1-3 Ikoinooka, Imabari City, Ehime, 794-8555, Japan
| | - T Furukawa
- Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan
| | - J L Shannonhouse
- Department of Oral & Maxillofacial Surgery, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA
| | - Y S Kim
- Department of Oral & Maxillofacial Surgery, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA; Programs in Integrated Biomedical Sciences & Translational Sciences, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA
| | - T Ishikawa
- Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuka, 52-1 Yada, Suruga Ward, Shizuoka City, Shizuoka, 422-8526, Japan.
| |
Collapse
|
2
|
Furukawa T, Kodama H, Ishii H, Kojima S, Nakajima T, Gan W, Velayutham T, Majid WA. Towards comprehensive understanding of piezoelectricity and its relaxation in VDF-based ferroelectric polymers. POLYMER 2023; 283:126235. [DOI: 10.1016/j.polymer.2023.126235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
3
|
Mat Zin S, Velayutham T, Furukawa T, Kodama H, Gan W, Chio-Srichan S, Kriechbaum M, Nakajima T. Quantitative study on the face shear piezoelectricity and its relaxation in uniaxially-drawn and annealed poly-l-lactic acid. POLYMER 2022. [DOI: 10.1016/j.polymer.2022.125095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Yoshikawa T, Furukawa T, Hashimoto T, Morimoto M, Azuma N, Matsui K. AB0401 THE BASELINE SERUM SOLUBLE TNF RECEPTOR LEVELS ARE ASSOCIATED WITH THE RESPONSE OF RHEUMATOID ARTHRITIS PATIENTS TO JAKinibs. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundRheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the multiple joints.The elucidation of the pathogenesis of RA has progressed dramatically in recent decades, and among the many cytokines involved in the pathogenesis of RA, interleukin (IL)-6 and TNF-α are known to be the major pro-inflammatory cytokines that are abundant in the bloodstream and synovial tissue. JAK inhibitors (JAKinibs) such as tofacitinib and baricitinib are used in the treatment of RA by inhibiting JAK, which in turn inhibits the signaling of various cytokines including IL-6. However, predictors of the response to JAKinibs are still required.ObjectivesWe aimed to combine soluble TNF receptor (sTNFR) I, sTNFR II, IL-6, soluble IL-6R (sIL-6R) and soluble gp130 (sgp130) levels to identify groups of JAKinibs responses in RA patients.MethodsThis research is a retrospective study. We reviewed medical records of RA patients initiating JAKinibs between July 2013 and July 2021 in our hospital. The Simplified Disease Activity Index (SDAI) was evaluated at baseline and 3, 6 months after JAKinibs administration. Clinical remission was defined when SDAI decreased ≤ 3.3. Of the 125 patients treated with JAKinibs, 89 patients with 6 months follow-up, valid SDAI and serum available were enrolled. Serum samples were tested for IL-6 (Human IL-6 Quantikine ELISA Kit, R&D systems), sIL-6R (Human soluble IL-6R alpha Quantikine ELISA Kit, R&D systems) and sgp130 (Human soluble gp130 Quantikine ELISA Kit, R&D systems), sTNFR I (Human TNF RI/TNFRSF1A Quantikine ELISA Kit DRT100) and sTNFR II (Human sTNF RII/TNFRSF1B Quantikine ELISA Kit DRT200) using specific ELISAs according to the manufacturer’s instructions. The statistical analyses were performed with EZR 1.55, and p values less than 0.05 were considered significant.ResultsThe median age of patients was 62 (IQR: 51 - 72) years and the median of disease duration was 6.0 (2.0 - 16.0) years. Twenty-seven (30.3%) patients were biologics and Jakinibs naive. The baseline SDAI was median 18.9 (12.7 - 27.9). When comparing SDAI-remission group (clinical remission: CR) and non-remission group, there were no significant differences in any of the baseline clinical parameters. There was no significant difference in the serum levels of IL-6, sIL-6R and sgp130 between the CR and non-CR groups, but the serum levels of sTNFR I and sTNFR II in the CR group were significantly lower than non-CR group. Univariate logistic regression analysis suggested Biologics and JAKinibs naive (odds ratio (OR) 3.58, p = 0.015), baseline Log sTNFR II levels (OR 0.013, P=0.034) as predictors of SDAI remission treated with JAKinibs at 6 months. Although not significant, Stage IV (OR 0.211, P=0.082) and baseline Log sTNFR I serum levels (OR 0.013, P=0.065) were associated with clinical remission.ConclusionRA patients could be easily stratified prior to JAKinibs intervention with serum sTNFR II and sTNFR I levels, not but IL-6 axis cytokines (IL-6, sIL-6R and sgp130).Univariate logistic regression analysis for clinical remission in patients treated with JAKinibs. Odds Ratio[95% C.I.]P ValueAge, year0.973[0.942 - 1.010]0.104Female (%)0.820[0.231 - 2.910]0.759BMI0.968[0.847 - 1.110]0.627Duration, year0.952[0.897 - 1.010]0.110StageIreferrenceII0.857[0.218 - 3.370]0.825III0.444[0.072 - 2.740]0.382IV0.211[0.036 - 1.220]0.082Biologic/JAKi naïve3.580[1.280 - 9.950]0.015JAKi Drug-Baricitinibreferrence-Tofacitinib1.780[0.659 - 4.800]0.256MTX use1.640[0.532 - 5.30]0.390PSL use0.476[0.176 - 1.290]0.143SASP use0.783[0.268 - 2.290]0.654IGU use0.328[0.039 - 2.750]0.304BUC use0.436[0.051 - 3.760]0.450TAC use0.233[0.029 - 1.910]0.1750W IL-6, pg/mL0.991[0.977 - 1.000]0.1980W sIL-6R, ng/mL0.983[0.947 - 1.02]0.3690W sgp130, ng/mL0.998[0.994 - 1.000]0.4440W sTNFR II/I ratio0.808[0.222 - 2.940]0.7460W Log sTNFR II, pg/mL0.002[0.0000653 - 0.634]0.0340W Log sTNFR I, pg/mL0.013[0.000126 - 1.300]0.065Disclosure of InterestsNone declared
Collapse
|
5
|
Yoshikawa T, Azuma K, Furukawa T, Hashimoto T, Morimoto M, Azuma N, Matsui K. AB0362 NEUTROPHIL COUNT REDUCTION 1 MONTH AFTER INITIATING SARILUMAB AND BASELINE SERUM SOLUBLE gp130 LEVELS CAN INDEPENDENTLY PREDICT CLINICAL REMISSION WITHIN 3 MONTH IN RHEUMATOID ARTHRITIS PATIENTS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundIL-6 contributes significantly to the chronic inflammatory process of rheumatoid arthritis (RA) and is elevated in serum and synovial fluid of RA patients.Sarilumab (SRL), a human anti-human IL-6 receptor alpha monoclonal antibody that blocks the signaling originated by the IL-6/IL-6R complex like tocilizumab (TCZ),is an effective treatment. Recently, an association between the therapeutic effect of TCZ and neutropenia after TCZ initiation was reported[1]. Neutropenia is a common adverse event of SRL in patients with RA, but the relationship between reduced neutrophil count and clinical response to SRL is still inconclusive. In EULAR 2020, we reported the association between serum soluble gp130 levels before SRL treatment and the efficacy of SRL[2]. It is also unclear whether there is a relationship between IL-6 axis cytokines and SRL-induced neutropenia.ObjectivesThe purpose of this study was to determine whether neutropenia at 1 month by SRL predicts clinical remission within 3 months and whether there is an association between IL-6 axis cytokines levels and SRL-induced neutropenia.MethodsThis research is a retrospective study. We reviewed medical records of RA patients initiating SRL between February 2018 and August 2021 in our hospital. The Clinical Disease Activity Index (CDAI) was evaluated at baseline (before initiating SRL) and 3 months after administration. Clinical remission was defined when CDAI decreased ≤ 2.8. Of the 66 patients treated with SRL, 42 patients with 3 months follow-up, valid CDAI and serum available were enrolled. The ratio of neutrophil counts 1 month after initiating SRL to those at baseline (neutrophil ratio) was also calculated. Serum samples were tested for IL-6 (Human IL-6 Quantikine ELISA Kit, R&D systems), sIL-6R (Human soluble IL-6R alpha Quantikine ELISA Kit, R&D systems) and sgp130 (Human soluble gp130 Quantikine ELISA Kit, R&D systems) using specific ELISAs according to the manufacturer’s instructions. The statistical analyses were performed with EZR 1.55, and p values less than 0.05 were considered significant.ResultsThe median age of patients was 69.0 (IQR: 59.3 - 73.8) years and the median of disease duration was 9.0 (3.0 - 16.0) years. Eighteen (42.9%) patients were biologics and Jakinibs naive. The baseline CDAI was median 16.7 (11.5 - 25.8). When comparing CDAI-remission group (clinical remission: CR) and non-CR group, Patients in the CR group had significantly shorter disease duration, were more Biologic and JAKinib naive, and had greater neutropenia 1 month after starting SRL (0.71 vs 0.94, P=0.0252). There was no significant difference in the baseline serum levels of IL-6, sIL-6R between the CR and non-CR groups, but baseline serum sgp130 levels in the CR group tended to be higher than in the non-CR group (264.9 vs 234.2 ng/mL, P=0.0592). Univariate logistic regression analysis suggested Biologics and JAKinibs naive (odds ratio (OR) 6.68, p = 0.0317), baseline serum sgp130 levels (OR 8.608, P=0.0312) as predictors of CDAI remission treated with SRL at 3 months. Although not significant, neutrophil ratio ≤ 0.8 was associated with achieving remission (OR 6.67, P=0.0537). Univariate logistic regression for neutrophil ratio ≤ 0.8 did not show any relevant factors, including higher baseline serum sgp130 levels (OR 1.25, P=0.782).ConclusionA 20% or greater decrease in neutrophil count after 1 month of SRL treatment and a high baseline serum sgp130 level independently predict clinical remission within 3 months.References[1]Nakajima T, Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, et al. Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients. Rheumatol Int. 2021;1rin[2]Yoshikawa T, Furukawa T, Tamura M, Hashimoto T, Morimoto M, Azuma N, et al. FRI0113 THE BASELINE SOLUBLE GP130 IS ASSOCIATED WITH THE RESPONSE OF RHEUMATOID ARTHRITIS PATIENTS TO SARILUMAB. Ann Rheum Dis. 2020;79(Suppl 1):637.1-637.Disclosure of InterestsNone declared
Collapse
|
6
|
Boulay F, Simpson GS, Ichikawa Y, Kisyov S, Bucurescu D, Takamine A, Ahn DS, Asahi K, Baba H, Balabanski DL, Egami T, Fujita T, Fukuda N, Funayama C, Furukawa T, Georgiev G, Gladkov A, Hass M, Imamura K, Inabe N, Ishibashi Y, Kawaguchi T, Kawamura T, Kim W, Kobayashi Y, Kojima S, Kusoglu A, Lozeva R, Momiyama S, Mukul I, Niikura M, Nishibata H, Nishizaka T, Odahara A, Ohtomo Y, Ralet D, Sato T, Shimizu Y, Sumikama T, Suzuki H, Takeda H, Tao LC, Togano Y, Tominaga D, Ueno H, Yamazaki H, Yang XF, Daugas JM. Boulay et al. Reply. Phys Rev Lett 2021; 127:169202. [PMID: 34723612 DOI: 10.1103/physrevlett.127.169202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Accepted: 08/31/2021] [Indexed: 06/13/2023]
Affiliation(s)
- F Boulay
- CEA, DAM, DIF, 91297 Arpajon cedex, France
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- GANIL, CEA/DSM-CNRS/IN2P3, BP55027, 14076 Caen cedex 5, France
| | - G S Simpson
- LPSC, CNRS/IN2P3, Université Joseph Fourier Grenoble 1, INPG, 38026 Grenoble Cedex, France
| | - Y Ichikawa
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Kisyov
- Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), 077125 Bucharest-Măgurele, Romania
| | - D Bucurescu
- Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), 077125 Bucharest-Măgurele, Romania
| | - A Takamine
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D S Ahn
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Asahi
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - H Baba
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D L Balabanski
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP), Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), 077125 Bucharest-Măgurele, Romania
| | - T Egami
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Advanced Sciences, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan
| | - T Fujita
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Osaka University, Machikaneyama 1-1 Toyonaka, Osaka 560-0034, Japan
| | - N Fukuda
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - C Funayama
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - T Furukawa
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Metropolitan University, 1-1 Minami-Ohsawa, Hachioji, Tokyo 192-0397, Japan
| | - G Georgiev
- CSNSM, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay Campus, France
| | - A Gladkov
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu 702-701, South Korea
| | - M Hass
- Department of Particle Physics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - K Imamura
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Meiji University, 1-1-1 Higashi-Mita, Tama, Kawasaki, Kanagawa 214-8571, Japan
| | - N Inabe
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Ishibashi
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-5877, Japan
| | - T Kawaguchi
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Advanced Sciences, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan
| | - T Kawamura
- Department of Physics, Osaka University, Machikaneyama 1-1 Toyonaka, Osaka 560-0034, Japan
| | - W Kim
- Department of Physics, Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu 702-701, South Korea
| | - Y Kobayashi
- Department of Informatics and Engineering, University of Electro-Communication, 1-5-1 Chofugaoka, Chohu, Tokyo 182-8585, Japan
| | - S Kojima
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - A Kusoglu
- CSNSM, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay Campus, France
- Department of Physics, Faculty of Science, Istanbul University, Vezneciler/Faith, 34134 Istanbul, Turkey
| | - R Lozeva
- CSNSM, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay Campus, France
| | - S Momiyama
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - I Mukul
- Department of Particle Physics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - M Niikura
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Nishibata
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Osaka University, Machikaneyama 1-1 Toyonaka, Osaka 560-0034, Japan
| | - T Nishizaka
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Advanced Sciences, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan
| | - A Odahara
- Department of Physics, Osaka University, Machikaneyama 1-1 Toyonaka, Osaka 560-0034, Japan
| | - Y Ohtomo
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - D Ralet
- CSNSM, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay Campus, France
| | - T Sato
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - Y Shimizu
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Sumikama
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Suzuki
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Takeda
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - L C Tao
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - D Tominaga
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Advanced Sciences, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan
| | - H Ueno
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Yamazaki
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - X F Yang
- Instituut voor Kern-en Stralingsfysica, K.U. Leuven, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - J M Daugas
- CEA, DAM, DIF, 91297 Arpajon cedex, France
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
7
|
Yoshikawa T, Azuma K, Furukawa T, Tamura M, Hashimoto T, Morimoto M, Azuma N, Matsui K. AB0311 INCREASED LEVELS OF SERUM WISTERIA FLORIBUNDA AGGLUTININPOSITIVE MAC-2 BINDING PROTEIN IN RHEUMATIC DISEASES INCLUDING SLE. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Mac-2 binding protein is a cell-adhesive glycoprotein of the extracellular matrix secreted as a ligand of galectin-3 (Mac-2). Recently, a Wisteria floribunda agglutinin positive-M2BP (M2BP) assay developed using a lectin-antibody sandwich immunoassay has shown promise as a new fibrotic marker in liver fibrosis and interstitial lung disease (ILD) to detect unique fibrosis-related glycoalteration.Objectives:The aim of this study is to evaluate the utility of serum Mac-2 binding protein glycosylation isomer (M2BPGi) levels in patients with rheumatic diseases (RD).Methods:We retrospectively measured serum M2BPGi levels in 68 patients with RD and 16 healthy controls (HC). There were no patients of cirrhosis and active hepatitis. Serum levels of M2BPGi were measured using HISCL M2BP glycosylation isomer Assay Kit. We examined the relationship between serum M2BPGi levels and clinical parameters in patients with RD.Results:In patients with RD, the median age was 62.0 years and 79.4% of them were female.Serum M2BPGi levels were significantly higher in patients with RD than in HC (median 0.98 cutoff index [COI], 0.32 COI, respectively; P < 0.00001). Patients with SLE tended to have higher serum M2BPGi levels than other rheumatic diseases.In patients with RD, a significant correlation was not found between serum M2BP levels and inflammation markers such as CRP or ferritin. However, serum M2BPGi levels were significantly correlated with B cell activation markers such as immunoglobulin free light chain and IgG (r = 0.588, 0.504) and T cell activation marker such as sIL-2R (r = 0.408).Conclusion:Most of the rheumatic diseases in this study were considered to be type I interferonopathy diseases such as rheumatoid arthritis, Sjogren’s syndrome, inflammatory myositis, scleroderma and SLE.Serum M2BPGi was reported to have a significant correlation with SLE disease activity [SS Ahn et al. Lupus. 2018; 27: 771], and also to have a significant correlation with Gakectin-9, a novel biomarker for IFN signiture [Lucas L van den Hoogen et al. Ann Rheum Dis. 2018; 77: 1810].So, it was suggested that serum M2BPGi may be a novel biomarker that indirectly indicates how much IFN is activated in rheumatic diseases.Disclosure of Interests:None declared
Collapse
|
8
|
Papola D, Ostuzzi G, Gastaldon C, Purgato M, Giovane CD, Pompoli A, Karyotaki E, Sijbrandij M, Furukawa T, Cuijpers P, Barbui C. Which psychotherapy is effective in panic disorder? Findings and reflections from a systematic network meta-analysis. Eur Psychiatry 2021. [PMCID: PMC9470392 DOI: 10.1192/j.eurpsy.2021.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Panic disorder is among the most prevalent anxiety diseases. Although psychotherapy is recommended as first-line treatment for panic disorder, little is known about the relative efficacy of different types of psychotherapies. Objectives To evaluate the effectiveness and acceptability of different types of psychotherapies for adults suffering from panic disorder, with or without agoraphobia. Methods We are conducting a systematic network meta-analysis of randomized controlled trials examining panic disorder. A comprehensive search was performed to identify relevant studies. The primary efficacy outcome is anxiety symptoms at study endpoint. The primary acceptability outcome is all-cause trial discontinuation at endpoint. Pairwise and network meta-analysis will be conducted. We are considering any kind of psychotherapy delivered by any therapist, as long as they were trained to deliver the therapy, or as self-help. Results To date we have identified 126 panic disorder and agoraphobia trials. The publication time span ranges from 1968 to 2020. We are now extracting data to provide an overview of the included study characteristics. The statistical analysis will be conducted between December 2020 and January 2021, and its results presented for the first time at the forthcoming 2021 EPA congress. Conclusions 126 trials on psychotherapy for panic disorders in adults are available. Because of this huge body of knowledge, it is important that the results of these studies are summarized using network meta-analytic techniques. The findings of this study will guide future research as knowledge gaps will be easily identified. Moreover, policymakers will have the opportunity to use this summarized knowledge to inform evidence-based decision making. Disclosure No significant relationships.
Collapse
|
9
|
Fuse K, Tanaka T, Shibasaki Y, Furukawa T, Narita M, Sone H, Masuko M. Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse-risk AML patients. Eur J Haematol 2020; 105:616-625. [PMID: 32705716 DOI: 10.1111/ejh.13495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Revised: 07/15/2020] [Accepted: 07/20/2020] [Indexed: 12/17/2022]
Abstract
INTRODUCTION Chromosome analysis is necessary for the risk classification of acute myeloid leukemia (AML). Marker chromosome (MC) is a fragmented chromosome whose origin cannot be identified from other chromosomes and originates from marked genomic instability. Although AML with MC (MC+) has a poor prognosis even after intensive chemotherapy, its influence on the outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is unclear. OBJECTIVE AND METHODS We retrospectively analyzed 162 AML patients after allo-HSCT. To evaluate the significance of MC, we compared it with other chromosomal abnormalities. RESULT Marker chromosome was detected in 14 (8.6%, MC+) patients (vs MC-, n = 158). The 2-year overall survival (OS) in MC+ vs MC- was 26.8% vs 62.2% (P = .0098). The 2-year cumulative incidence of relapse (CIR) in MC+ vs MC- was 80.4% vs 35.5% (P = .0004). Among adverse-risk AML (AD-AML, n = 36), AD-AML/MC+ (n = 11) demonstrated a poorer 2-year OS (9.1%, vs AD-AML/MC- n = 25, 58.3%, P = .0031) and higher 2-year CIR (89.6%, vs AD-AML/MC- 44.7%, P = .002). In multivariate analysis, MC (HR 3.08, 95% CI; 1.02-9.29, P = .046) and HCT-CI (HR 3.23, 95% CI; 1.00-10.4, P = .049) were independent risk factors for CIR among AD-AML. CONCLUSION Our study suggests MC as a new independent factor for chromosome risk classification to further classify AD-AML.
Collapse
Affiliation(s)
- Kyoko Fuse
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine Graduate School of Medical and Dental Science, Niigata University, Niigata, Japan
| | - Tomoyuki Tanaka
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine Graduate School of Medical and Dental Science, Niigata University, Niigata, Japan
| | - Yasuhiko Shibasaki
- Department of Hematopoietic Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - Tatsuo Furukawa
- Department of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Japan
| | - Miwako Narita
- Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan
| | - Hirohito Sone
- Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine Graduate School of Medical and Dental Science, Niigata University, Niigata, Japan
| | - Masayoshi Masuko
- Department of Hematopoietic Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan
| |
Collapse
|
10
|
Azuma N, Furukawa T, Shima Y, Matsui K. FRI0227 A USABILITY SURVEY OF WRIST MOUNTED DISPOSABLE HEAT PAD ON RAYNAUD’S PHENOMENON IN PATIENTS WITH CONNECTIVE TISSUE DISEASES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:For patients with connective tissue diseases (CTD), vasodilators are used to treat Raynaud’s phenomenon (RP), they are difficult to control only by medication. Although physicians recommend the use of a portable handwarmer or gloves to patients with CTD presenting with RP, sustained heat-retention effects cannot be obtained from them because the patients’ daily life-related activities prevent their continued use. Since the wrist mounted disposable heat pad maintains the degrees of freedom of the hands and fingers and can remain usable during the daily activities, we considered this heat pad as a useful and highly practical heating method for CTD patients presenting with RP.Objectives:To investigate the usability and changes in symptoms resulting from the use of the wrist mounted disposable heat pad in CTD patients presenting with RP.Methods:Subjects were 23 outpatients with CTD presenting with RP (23 females; mean age 62.6 years; mean duration following the onset of RP 10.3 years; 12 systemic sclerosis, 5 mixed connective tissue disease, 5 Sjögren’s syndrome, and 1 systemic lupus erythematosus) who had used the wrist mounted disposable heat pad (put the pad in a specifically designed holder and wrap it around wrist joint (max. temperature 42 degrees Celsius, heat-retention time 6 hours)). We investigated through interviews with them the use situations, usability, and changes in RP. During their using the heat pad, medication and daily life-related precautions against RP continued to be implemented as before.Results:Many patients had no knowledge of the heat pad (n=17, 73.9%). The most common wearing time of the heat pad was 5–6 hours (n=8, 34.8%). As for scenes of wearing the heat pad, patients who wore the pad when being out of the home accounted for the highest proportion (n=16, 69.6%), and as follows: at home (n=6, 26.1%), during kitchen work (n=3, 13.0%), and during housework (n=2, 8.7%). 17 patients (73.9%) replied that usability was “good”, and 18 (78.3%) replied that usability was “better” compared with conventional measures. Moreover, many patients (n=16, 69.6%) replied that RP and associated symptoms had become reduced or alleviated. No patients replied that RP and associated symptoms had become exacerbated or severer. In terms of advantages of using the heat pad, patients who replied that the site on which the pad was mounted was felt to be warm accounted for the highest proportion (n=8, 34.8%), and those who replied that sites other than where the pad was mounted (such as fingertips, hands, and arms) were also warmed accounted for virtually the same proportion (n=7, 30.4%). Over 60% of the patients (n=14, 60.9%) replied that symptoms associated with RP (skin color, cold sensation, and pain) had become reduced or disappeared. In terms of disadvantages of using the heat pad, patients who replied that it was bothersome to use the pad accounted for the highest proportion while other patients made replies referring to cost and bad appearance. No significant accident occurred and as many as 17 patients (73.9%) replied that they would like to continue to use the heat pad in the future.Conclusion:There have been few reports evaluating the usefulness of a heat pad for RP. The wrist mounted disposable heat pad was thought to be a heating method having the potential to achieve high levels of usability and practicality on CTD patients presenting with RP. Given that the heat pad alleviated RP or caused sites other than where the pad was mounted to be felt warm even though it did not directly heat the hands and fingers, the pad seemed to have usefulness attributed to the heating of the wrist. Although the heat pad seems to be an excellent method for addressing RP in patients’ daily lives, we hope that this heat pad will be evaluated on a larger number of patients with the addition of objective indices.References:[1]Koscheyev VS, et al. Aviat Space Environ Med. 72: 713-719, 2001.Disclosure of Interests:Naoto Azuma: None declared, Tetsuya Furukawa: None declared, Yoshihito Shima Grant/research support from: Endowed chair funded by/accepted a researcher from Kirikai Chemical and Kobayashi Pharmaceutical., Kiyoshi Matsui Grant/research support from: Asahi Kasei Pharma, Astellas Pharma (research grants), Speakers bureau: Bristol-Myers Squibb (lecture fees)
Collapse
|
11
|
Yoshikawa T, Furukawa T, Tamura M, Hashimoto T, Morimoto M, Azuma N, Matsui K. FRI0113 THE BASELINE SOLUBLE GP130 IS ASSOCIATED WITH THE RESPONSE OF RHEUMATOID ARTHRITIS PATIENTS TO SARILUMAB. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:IL-6 contributes significantly to the chronic inflammatory process of rheumatoid arthritis (RA). Sarilumab (SRL), a human anti-human IL-6 receptor alpha monoclonal antibody that blocks the signaling originated by the IL-6/IL-6R complex like tocilizumab,is an effective treatment. However, predictors of the response to sarilumab are still required.Objectives:We aimed to combine IL-6, soluble IL-6R (sIL-6R) and gp130 (sgp130) levels to identify groups of sarilumab responses.Methods:This research is a retrospective study. a total of 32 RA patients with SRL therapy in our department from February 1 in 2018 to December 31 in 2019 were included. Serum and clinical data from 32 RA patients were collected before treatment and until the last visit. Follow-up period was up to one year after starting SRL treatment. Serum were tested for IL-6 (Human IL-6 Quantikine ELISA Kit, R&D systems), sIL-6R (Human soluble IL-6R alpha Quantikine ELISA Kit, R&D systems) and sgp130 (Human soluble gp130 Quantikine ELISA Kit, R&D systems), using specific ELISAs according to the manufacturer’s instructions. Hierarchical cluster analysis (JMP14.3.0) was used to establish the relationship between IL-6, sIL-6R and sgp130. We evaluated the efficacy of SRL treatment on the last visit using European League Against Rheumatism (EULAR) response criteria in the groups of patients. The other statistical analyses were performed with EZR 1.41, and p Values less than 0.05 were considered significant.Results:The median age of patients was 70.5 (IQR: 66.5-74.3) years and the median of disease duration was 7.3 (1.7-15.3) years. Nine (28.1%) patients were biologics and Jakinibs naive. the median follow-up periods were 24 (12-26) weeks. The baseline DAS28 was median 4.39 (3.77 - 5.43), and CDAI was 21.1 (11.7-29.5). When comparing responders and non-responders, there were no significant differences in any of the baseline parameters and cytokines. Four statistical significant clusters of RA patients (i.e., Group1, Group2, Group3 and tocilizumab use group before SRL) were defined by serum concentrations of IL-6, sIL-6R and spg130 at baseline. The levels of IL-6 expressed as median in Group1 patients were 25.6 (14.4–72.2) pg/ml, in Group2 5.9 (3.3–11.3) pg/ml, and in Group3 70.2 (45.4–86.1) pg/ml (p < 0.002, significant difference only between Group2 and Group3). The levels of sIL-6R expressed as median in Group1 patients were 38.7 (34.7-45.1) ng/ml, in Group2 35.1 (24.8-41.9) ng/ml, and in Group3 35.7 (34.2-39.8) ng/ml (p = 0.5477). The levels of sgp130 expressed as median in Group1 patients were 272.6 (263.0-277.2) ng/ml, in Group2 223.1 (221.0-228.0) ng/ml, and in Group3 204.6 (192.0-207.6) ng/ml (p < 0.00003, significant difference between the three groups respectively). There were no significant differences in any of the baseline clinical features and laboratory findings between the three groups. Out of the 8 patients in Group1 had a good or moderate response to SRL. Conversely, the percentage of patients with no response to SRL was higher in Group3 than in Group1 and Group2.Conclusion:RA patients could be easily stratified prior to the rapeutic intervention with sgp130 related to the IL-6 signal reguration. Group1 patients, who had the best response to SRL, had the highest level of sgp130.Table 1.Comparison of baseline serum IL-6, sIL-6R and sgp130 of each groups of patientsTCZ use before SRLGroup 1Group 2Group 3P valuen=3N=9N=8N=9IL-6,pg/mL69.8,77.6,592.6Median[IQR]25.6[14.4-72.2]5.9[3.3-11.3]70.2[45.4-86.1]<0.002csIL-6R,ng/mL390.5,413.2,481.7Median[IQR]38.7[34.7-45.1]35.1[24.8-41.9]35.7[34.2-39.8]0.547sgp130,ng/mL205.6,219.2,239.8Median[IQR]273[263-277]223[221-228]205[192-208]<0.001abc*a, b and c mean that statically significant difference between subgroups as a: group1 vs. 2, b: group 1 vs. 3, c: group 2 vs. 3.Disclosure of Interests:Takahiro Yoshikawa: None declared, Tetsuya Furukawa: None declared, Masao Tamura: None declared, Teppei Hashimoto: None declared, Mai Morimoto: None declared, Naoto Azuma: None declared, Kiyoshi Matsui Grant/research support from: Asahi Kasei Pharma, Astellas Pharma (research grants), Speakers bureau: Bristol-Myers Squibb (lecture fees)
Collapse
|
12
|
Boulay F, Simpson GS, Ichikawa Y, Kisyov S, Bucurescu D, Takamine A, Ahn DS, Asahi K, Baba H, Balabanski DL, Egami T, Fujita T, Fukuda N, Funayama C, Furukawa T, Georgiev G, Gladkov A, Hass M, Imamura K, Inabe N, Ishibashi Y, Kawaguchi T, Kawamura T, Kim W, Kobayashi Y, Kojima S, Kusoglu A, Lozeva R, Momiyama S, Mukul I, Niikura M, Nishibata H, Nishizaka T, Odahara A, Ohtomo Y, Ralet D, Sato T, Shimizu Y, Sumikama T, Suzuki H, Takeda H, Tao LC, Togano Y, Tominaga D, Ueno H, Yamazaki H, Yang XF, Daugas JM. g Factor of the ^{99}Zr (7/2^{+}) Isomer: Monopole Evolution in the Shape-Coexisting Region. Phys Rev Lett 2020; 124:112501. [PMID: 32242689 DOI: 10.1103/physrevlett.124.112501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 11/28/2019] [Accepted: 12/17/2019] [Indexed: 06/11/2023]
Abstract
The gyromagnetic factor of the low-lying E=251.96(9) keV isomeric state of the nucleus ^{99}Zr was measured using the time-dependent perturbed angular distribution technique. This level is assigned a spin and parity of J^{π}=7/2^{+}, with a half-life of T_{1/2}=336(5) ns. The isomer was produced and spin aligned via the abrasion-fission of a ^{238}U primary beam at RIKEN RIBF. A magnetic moment |μ|=2.31(14)μ_{N} was deduced showing that this isomer is not single particle in nature. A comparison of the experimental values with interacting boson-fermion model IBFM-1 results shows that this state is strongly mixed with a main νd_{5/2} composition. Furthermore, it was found that monopole single-particle evolution changes significantly with the appearance of collective modes, likely due to type-II shell evolution.
Collapse
Affiliation(s)
- F Boulay
- CEA, DAM, DIF, 91297 Arpajon cedex, France
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- GANIL, CEA/DSM-CNRS/IN2P3, BP55027, 14076 Caen cedex 5, France
| | - G S Simpson
- LPSC, CNRS/IN2P3, Université Joseph Fourier Grenoble 1, INPG, 38026 Grenoble Cedex, France
| | - Y Ichikawa
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Kisyov
- Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), 077125 Bucharest-Măgurele, Romania
| | - D Bucurescu
- Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), 077125 Bucharest-Măgurele, Romania
| | - A Takamine
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D S Ahn
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Asahi
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - H Baba
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D L Balabanski
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Extreme Light Infrastructure-Nuclear Physics (ELI-NP), Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), 077125 Bucharest-Măgurele, Romania
| | - T Egami
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Advanced Sciences, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan
| | - T Fujita
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Osaka University, Machikaneyama 1-1 Toyonaka, Osaka 560-0034, Japan
| | - N Fukuda
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - C Funayama
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - T Furukawa
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Metropolitan University, 1-1 Minami-Ohsawa, Hachioji, Tokyo 192-0397, Japan
| | - G Georgiev
- CSNSM, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay Campus, France
| | - A Gladkov
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu 702-701, South Korea
| | - M Hass
- Department of Particle Physics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - K Imamura
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Meiji University, 1-1-1 Higashi-Mita, Tama, Kawasaki, Kanagawa 214-8571, Japan
| | - N Inabe
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Ishibashi
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-5877, Japan
| | - T Kawaguchi
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Advanced Sciences, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan
| | - T Kawamura
- Department of Physics, Osaka University, Machikaneyama 1-1 Toyonaka, Osaka 560-0034, Japan
| | - W Kim
- Department of Physics, Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu 702-701, South Korea
| | - Y Kobayashi
- Department of Informatics and Engineering, University of Electro-Communication, 1-5-1 Chofugaoka, Chohu, Tokyo 182-8585, Japan
| | - S Kojima
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - A Kusoglu
- CSNSM, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay Campus, France
- Department of Physics, Faculty of Science, Istanbul University, Vezneciler/Faith, 34134 Istanbul, Turkey
| | - R Lozeva
- CSNSM, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay Campus, France
| | - S Momiyama
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - I Mukul
- Department of Particle Physics, Weizmann Institute of Science, Rehovot 76100, Israel
| | - M Niikura
- Department of Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Nishibata
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Osaka University, Machikaneyama 1-1 Toyonaka, Osaka 560-0034, Japan
| | - T Nishizaka
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Advanced Sciences, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan
| | - A Odahara
- Department of Physics, Osaka University, Machikaneyama 1-1 Toyonaka, Osaka 560-0034, Japan
| | - Y Ohtomo
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - D Ralet
- CSNSM, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay Campus, France
| | - T Sato
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - Y Shimizu
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Sumikama
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Suzuki
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Takeda
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - L C Tao
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing 100871, China
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, 2-12-1 Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - D Tominaga
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Advanced Sciences, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan
| | - H Ueno
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Yamazaki
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - X F Yang
- Instituut voor Kern- en Stralingsfysica, K.U. Leuven, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - J M Daugas
- CEA, DAM, DIF, 91297 Arpajon cedex, France
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
13
|
Fuse K, Uemura S, Tamura S, Suwabe T, Katagiri T, Tanaka T, Ushiki T, Shibasaki Y, Sato N, Yano T, Kuroha T, Hashimoto S, Furukawa T, Narita M, Sone H, Masuko M. Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. Cancer Med 2019; 8:5058-5067. [PMID: 31305031 PMCID: PMC6718546 DOI: 10.1002/cam4.2401] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2019] [Revised: 06/23/2019] [Accepted: 06/24/2019] [Indexed: 12/23/2022] Open
Abstract
Although allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a curative therapy for high‐risk acute leukemia (AL), some patients still relapse. Since patients simultaneously have many prognostic factors, difficulties are associated with the construction of a patient‐based prediction algorithm of relapse. The alternating decision tree (ADTree) is a successful classification method that combines decision trees with the predictive accuracy of boosting. It is a component of machine learning (ML) and has the capacity to simultaneously analyze multiple factors. Using ADTree, we attempted to construct a prediction model of leukemia relapse within 1 year of transplantation. With the model of training data (n = 148), prediction accuracy, the AUC of ROC, and the κ‐statistic value were 78.4%, 0.746, and 0.508, respectively. The false positive rate (FPR) of the relapse prediction was as low as 0.134. In an evaluation of the model with validation data (n = 69), prediction accuracy, AUC, and FPR of the relapse prediction were similar at 71.0%, 0.667, and 0.216, respectively. These results suggest that the model is generalized and highly accurate. Furthermore, the output of ADTree may visualize the branch point of treatment. For example, the selection of donor types resulted in different relapse predictions. Therefore, clinicians may change treatment options by referring to the model, thereby improving outcomes. The present results indicate that ML, such as ADTree, will contribute to the decision‐making process in the diversified allo‐HSCT field and be useful for preventing the relapse of leukemia.
Collapse
Affiliation(s)
- Kyoko Fuse
- Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan
| | - Shun Uemura
- Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan
| | - Suguru Tamura
- Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan
| | - Tatsuya Suwabe
- Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan
| | - Takayuki Katagiri
- Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan
| | - Tomoyuki Tanaka
- Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan
| | - Takashi Ushiki
- Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan
| | - Yasuhiko Shibasaki
- Department of Hematopoietic Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - Naoko Sato
- Department of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Japan
| | - Toshio Yano
- Department of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Japan
| | - Takashi Kuroha
- Department of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Japan
| | - Shigeo Hashimoto
- Department of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Japan
| | - Tatsuo Furukawa
- Department of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Japan
| | - Miwako Narita
- Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan
| | - Hirohito Sone
- Faculty of Medicine, Department of Hematology, Endocrinology and Metabolism, Niigata University, Niigata, Japan
| | - Masayoshi Masuko
- Department of Hematopoietic Cell Transplantation, Niigata University Medical and Dental Hospital, Niigata, Japan
| |
Collapse
|
14
|
Maruyama T, Takashima H, Tei R, Furukawa T, Maruyama N, Abe M. MON-300 EFFICACY AND SAFETY OF CANAGLIFLOZIN, A SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR, IN DIABETIC KIDNEY DISEASE: A RANDOMIZED OPEN-LABEL PROSPECTIVE TRIAL. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.1109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
15
|
Chen FQ, Kono N, Suzuki R, Furukawa T, Tanuma H, Ferrari P, Azuma T, Matsumoto J, Shiromaru H, Zhaunerchyk V, Hansen K. Radiative cooling of cationic carbon clusters, C N+, N = 8, 10, 13-16. Phys Chem Chem Phys 2019; 21:1587-1596. [PMID: 30620033 DOI: 10.1039/c8cp06368k] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The radiative cooling of highly excited carbon cluster cations of sizes N = 8, 10, 13-16 has been studied in an electrostatic storage ring. The cooling rate constants vary with cluster size from a maximum at N = 8 of 2.6 × 104 s-1 and a minimum at N = 13 of 4.4 × 103 s-1. The high rates indicate that photon emission takes place from electronically excited ions, providing a strong stabilizing cooling of the molecules.
Collapse
Affiliation(s)
- F-Q Chen
- School of Materials Science and Engineering, Tianjin University, Tianjin 300350, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Nakaya H, Yokoyama N, Kataoka A, Watanabe Y, Kumiko K, Furukawa T, Kozuma K. P5442Prevalence and predictors of atherosclerotic peripheral arterial obstructive disease in heart valve disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- H Nakaya
- Teikyo University School of Medicine, Tokyo, Japan
| | - N Yokoyama
- Teikyo University School of Medicine, Tokyo, Japan
| | - A Kataoka
- Teikyo University School of Medicine, Tokyo, Japan
| | - Y Watanabe
- Teikyo University School of Medicine, Tokyo, Japan
| | - K Kumiko
- Teikyo University School of Medicine, Tokyo, Japan
| | - T Furukawa
- Teikyo University Hospital, Laboratory Medicine, Tokyo, Japan
| | - K Kozuma
- Teikyo University School of Medicine, Tokyo, Japan
| |
Collapse
|
17
|
Shibasaki Y, Suwabe T, Katagiri T, Tanaka T, Ushiki T, Fuse K, Sato N, Yano T, Kuroha T, Hashimoto S, Narita M, Furukawa T, Sone H, Masuko M. Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. Int J Hematol 2018; 108:282-289. [DOI: 10.1007/s12185-018-2463-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Revised: 04/26/2018] [Accepted: 04/26/2018] [Indexed: 10/16/2022]
|
18
|
Furukawa T, Takizawa K, Yano K, Kuwahara D, Shinohara S. Spatial measurement in rotating magnetic field plasma acceleration method by using two-dimensional scanning instrument and thrust stand. Rev Sci Instrum 2018; 89:043505. [PMID: 29716344 DOI: 10.1063/1.5013214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
A two-dimensional scanning probe instrument has been developed to survey spatial plasma characteristics in our electrodeless plasma acceleration schemes. In particular, diagnostics of plasma parameters, e.g., plasma density, temperature, velocity, and excited magnetic field, are essential for elucidating physical phenomena since we have been concentrating on next generation plasma propulsion methods, e.g., Rotating Magnetic Field plasma acceleration method, by characterizing the plasma performance. Moreover, in order to estimate the thrust performance in our experimental scheme, we have also mounted a thrust stand, which has a target type, on this movable instrument, and scanned the axial profile of the thrust performance in the presence of the external magnetic field generated by using permanent magnets, so as to investigate the plasma captured in a stand area, considering the divergent field lines in the downstream region of a generation antenna. In this paper, we will introduce the novel measurement instrument and describe how to measure these parameters.
Collapse
Affiliation(s)
- T Furukawa
- The Graduate School of Engineering, Tokyo University of Agriculture and Technology, Tokyo 184-8588, Japan
| | - K Takizawa
- The Graduate School of Engineering, Tokyo University of Agriculture and Technology, Tokyo 184-8588, Japan
| | - K Yano
- The Graduate School of Engineering, Tokyo University of Agriculture and Technology, Tokyo 184-8588, Japan
| | - D Kuwahara
- Institute of Engineering, Tokyo University of Agriculture and Technology, Tokyo 184-8588, Japan
| | - S Shinohara
- Institute of Engineering, Tokyo University of Agriculture and Technology, Tokyo 184-8588, Japan
| |
Collapse
|
19
|
Mahdi R, Gan W, Abd Majid W, Mukri NI, Furukawa T. Ferroelectric polarization and pyroelectric activity of functionalized P(VDF-TrFE) thin film lead free nanocomposites. POLYMER 2018. [DOI: 10.1016/j.polymer.2018.03.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, Furukawa T, Nara M, Matsuo K, Akashi K, Taniguchi S, Harada M, Teshima T. Myeloablative Versus Reduced-Intensity Conditioning in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Using Posttransplant Cyclophosphamide. Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Matsui N, Nodera H, Kuzume D, Iwasa N, Unai Y, Sakai W, Miyazaki Y, Yamazaki H, Osaki Y, Mori A, Furukawa T, Tsukamoto-Miyashiro A, Shimatani Y, Yamasaki M, Izumi Y, Kusunoki S, Arisawa K, Kaji R. Guillain−Barré syndrome in a local area in Japan, 2006-2015: an epidemiological and clinical study of 108 patients. Eur J Neurol 2018; 25:718-724. [DOI: 10.1111/ene.13569] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Accepted: 01/08/2018] [Indexed: 11/30/2022]
Affiliation(s)
- N. Matsui
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - H. Nodera
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - D. Kuzume
- Department of Neurology; Chikamori Hospital; Kochi Japan
| | - N. Iwasa
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - Y. Unai
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - W. Sakai
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - Y. Miyazaki
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - H. Yamazaki
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - Y. Osaki
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - A. Mori
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - T. Furukawa
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - A. Tsukamoto-Miyashiro
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - Y. Shimatani
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - M. Yamasaki
- Department of Neurology; Chikamori Hospital; Kochi Japan
| | - Y. Izumi
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| | - S. Kusunoki
- Department of Neurology; Kindai University; Faculty of Medicine; Osaka Japan
| | - K. Arisawa
- Department of Preventive Medicine; Institute of Biomedical Sciences; Tokushima University Graduate School; Tokushima Japan
| | - R. Kaji
- Department of Clinical Neuroscience; Graduate School of Biomedical Sciences; Tokushima University; Tokushima Japan
| |
Collapse
|
22
|
Hirose K, Aoki T, Furukawa T, Fukushima S, Niioka H, Deguchi S, Hashimoto M. Coherent anti-Stokes Raman scattering rigid endoscope toward robot-assisted surgery. Biomed Opt Express 2018; 9:387-396. [PMID: 29552380 PMCID: PMC5854045 DOI: 10.1364/boe.9.000387] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 12/16/2017] [Accepted: 12/18/2017] [Indexed: 05/16/2023]
Abstract
Label-free visualization of nerves and nervous plexuses will improve the preservation of neurological functions in nerve-sparing robot-assisted surgery. We have developed a coherent anti-Stokes Raman scattering (CARS) rigid endoscope to distinguish nerves from other tissues during surgery. The developed endoscope, which has a tube with a diameter of 12 mm and a length of 270 mm, achieved 0.91% image distortion and 8.6% non-uniformity of CARS intensity in the whole field of view (650 μm diameter). We demonstrated CARS imaging of a rat sciatic nerve and visualization of the fine structure of nerve fibers.
Collapse
Affiliation(s)
- K. Hirose
- Graduate School of Engineering Science, Osaka University, Osaka,
Japan
| | - T. Aoki
- Graduate School of Engineering Science, Osaka University, Osaka,
Japan
| | - T. Furukawa
- Faculty of Engineering, Yokohama National University, Yokohama,
Japan
| | - S. Fukushima
- Graduate School of Engineering Science, Osaka University, Osaka,
Japan
| | - H. Niioka
- Graduate School of Engineering Science, Osaka University, Osaka,
Japan
| | - S. Deguchi
- Graduate School of Engineering Science, Osaka University, Osaka,
Japan
| | - M. Hashimoto
- Graduate School of Information Science and Technology, Hokkaido University, Hokkaido,
Japan
| |
Collapse
|
23
|
Yoshikawa M, Furukawa T, Kubota Y, Sedo K, Kobayashi T, Takemura Y, Ishii K, Cho T, Yatsu K, Kawamori E, Okamoto Y, Yamaguchi N. Study of Impurity Ions Behavior in The Gamma 10 Plasma. Fusion Science and Technology 2018. [DOI: 10.13182/fst03-a11963592] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Yoshikawa
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Furukawa
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Kubota
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - K. Sedo
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Kobayashi
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Takemura
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - K. Ishii
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Cho
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - K. Yatsu
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - E. Kawamori
- High Temperature Plasma Center, University of Tokyo, Tokyo 113-8656, Japan
| | - Y. Okamoto
- Toyota Technological Institute, Tenpaku, Nagoya, Aichi 468-8511, Japan
| | - N. Yamaguchi
- Toyota Technological Institute, Tenpaku, Nagoya, Aichi 468-8511, Japan
| |
Collapse
|
24
|
Kanemura T, Kondo H, Furukawa T, Hirakawa Y, Wakai E, Knaster J. Analytical and experimental study of the evaporation and deposition rates from a high-speed liquid lithium jet. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.08.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Shibasaki Y, Suwabe T, Katagiri T, Tanaka T, Kobayashi H, Fuse K, Ushiki T, Sato N, Yano T, Kuroha T, Hashimoto S, Narita M, Furukawa T, Sone H, Masuko M. The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. Clin Transplant 2017; 31. [DOI: 10.1111/ctr.13103] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/29/2017] [Indexed: 01/19/2023]
Affiliation(s)
- Yasuhiko Shibasaki
- Department of Hematopoietic Cell Transplantation; Niigata University Medical and Dental Hospital; Niigata City Japan
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Tatsuya Suwabe
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Takayuki Katagiri
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Tomoyuki Tanaka
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Hironori Kobayashi
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Kyoko Fuse
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Takashi Ushiki
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Naoko Sato
- Department of Hematology; Nagaoka Red Cross Hospital; Nagaoka City Japan
| | - Toshio Yano
- Department of Hematology; Nagaoka Red Cross Hospital; Nagaoka City Japan
| | - Takashi Kuroha
- Department of Hematology; Nagaoka Red Cross Hospital; Nagaoka City Japan
| | - Shigeo Hashimoto
- Department of Hematology; Nagaoka Red Cross Hospital; Nagaoka City Japan
| | - Miwako Narita
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Tatsuo Furukawa
- Department of Hematology; Nagaoka Red Cross Hospital; Nagaoka City Japan
| | - Hirohito Sone
- Department of Hematology; Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata City Japan
| | - Masayoshi Masuko
- Department of Hematopoietic Cell Transplantation; Niigata University Medical and Dental Hospital; Niigata City Japan
| |
Collapse
|
26
|
Hanada K, Matsui N, Nodera H, Kuzume D, Sato K, Iwasa N, Unai Y, Sakai W, Miyazaki Y, Yamazaki H, Osaki Y, Furukawa T, Yamasaki M, Izumi Y, Kusunoki S, Arisawa K, Kaji R. Guillain-Barré syndrome in a local area in Japan, 2006-2015: An epidemiological and clinical study of 108 patients. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Hosokai R, Masuko M, Shibasaki Y, Saitoh A, Furukawa T, Imai C. Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell–Replete Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2017; 23:606-611. [DOI: 10.1016/j.bbmt.2016.12.638] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2016] [Accepted: 12/27/2016] [Indexed: 12/16/2022]
|
28
|
Wakai E, Kondo H, Kanemura T, Furukawa T, Hirakawa Y, Watanabe K, Ida M, Ito Y, Niitsuma S, Edao Y, Fujishiro K, Nakaniwa K, Hoashi E, Horiike H, Serizawa H, Kawahito Y, Fukada S, Sugie Y, Suzuki A, Yagi J, Tsuji Y, Furuya K, Groeschel F, KNASTER J, MICCHICHE G, IBARRA A, HEIDINGER R, NITTI F, SUGIMOTO M. Engineering Validation and Engineering Design of Lithium Target Facility in IFMIF/EVEDA Project. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-770] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- E. Wakai
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - H. Kondo
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - T. Kanemura
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - T. Furukawa
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - Y. Hirakawa
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - K. Watanabe
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - M. Ida
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - Y. Ito
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - S. Niitsuma
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - Y. Edao
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - K. Fujishiro
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | - K. Nakaniwa
- Japan Atomic Energy Agency, Ibaraki 319-1195, Japan
| | | | | | | | | | | | - Y. Sugie
- Kyushu University, Fukuoka, Japan
| | | | - J. Yagi
- National Institute for Fusion Science, Gifu, Japan
| | | | | | - F. Groeschel
- Project Team of IFMIF/EVEDA Project, Aomori, Japan
| | - J. KNASTER
- Project Team of IFMIF/EVEDA Project, Aomori, Japan
| | | | | | | | - F. NITTI
- Project Team of IFMIF/EVEDA Project, Aomori, Japan
- ENEA, Brasimone, Italy
| | | |
Collapse
|
29
|
Wakai E, Kanemura T, Kondo H, Hirakawa Y, Ito Y, Serizawa H, Kawahito Y, Higashi T, Suzuki A, Fukada S, Furuya K, Esaki K, Yagi J, Tsuji Y, Ito T, Niitsuma S, Yoshihashi-Suzuki S, Watanabe K, Furukawa T, Groeschel F, Micciche G, Manorri S, Favuzza P, Nitti F, Heidinger R, Terai T, Horiike H, Sugimoto M, Ohira S, Knaster J. Engineering validation for lithium target facility of the IFMIF under IFMIF/EVEDA project. Nuclear Materials and Energy 2016. [DOI: 10.1016/j.nme.2016.05.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Ozawa T, Kato K, Sanada H, Makiyama Y, Saigawa T, Souda S, Hashimoto S, Furukawa T, Toba K, Kodama M, Fujiwara H, Namura O, Hayashi J, Yoshimura N, Aizawa Y. Marked Decrease of Plasma VEGF After Implantation of Autologous Bone Marrow Mononuclear Cells in a Patient with Critical Limb Ischemia. Angiology 2016; 57:235-9. [PMID: 16518534 DOI: 10.1177/000331970605700216] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The authors performed autologous bone marrow mononuclear cells implantation (BMI) in a 79-year-old man with critical limb ischemia. After BMI, the resting pain of the ischemic leg improved gradually. They measured the plasma concentrations of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and serum hepatocyte growth factor (HGF) in the blood from bilateral femoral veins. Before BMI, the plasma VEGF and bFGF concentrations were much greater in the ischemic leg than in the other lower limb, but decreased to the same concentrations as those in the contralateral lower extremity after BMI. The large concentrations of the angiogenic factors VEGF and bFGF in plasma indicate the severity and extent of the leg ischemia. BMI resulted in lower levels of VEGF and bFGF, and this fall is the hallmark of the effectiveness of BMI in the treatment of peripheral artery disease.
Collapse
Affiliation(s)
- Takuya Ozawa
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences, Niigata-City, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
Ultrasonographic (US) angiography was performed by sonographic examination with injection of carbon dioxide microbubbles through a catheter following conventional angiography in 41 patients with various gallbladder diseases. Three enhancement patterns were found; strong enhancement in the lesion from the periphery to the center was noted in patients with adenocarcinoma and benign polyp (type I), irregular partial enhancement at the margins of the lesion in those with adenosquamous carcinoma (type II), and internal regular enhancement in those with chronic cholecystitis, xanthogranulomatous cholecystitis and adenomyomatosis (type III). Pseudopolypoid lesion such as gallbladder debris showed no enhancement. US angiography may be useful in the differential diagnosis of gallbladder diseases, especially to differentiate the wall thickening type of gallbladder carcinoma from chronic cholecystitis or adenomyomatosis, and the pseudopolypoid lesion and fundal type of adenomyomatosis from benign polyp or polypoid-type carcinoma.
Collapse
|
32
|
Furukawa T, Matsui K, Kitano M, Kitano S, Yokoyama Y, Sekiguchi M, Azuma N, Sano H. AB0646 The Role of Serum YKL-40 in Systemic Sclerosis (SSC). Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
33
|
Favuzza P, Antonelli A, Furukawa T, Groeschel F, Hedinger R, Higashi T, Hirakawa Y, Iijima M, Ito Y, Kanemura T, Knaster J, Kondo H, Miccichè G, Nitti F, Ohira S, Severi M, Sugimoto M, Suzuki A, Traversi R, Wakai E. Round Robin test for the determination of nitrogen concentration in solid Lithium. Fusion Engineering and Design 2016. [DOI: 10.1016/j.fusengdes.2016.03.026] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Saotome N, Furukawa T, Mizushima K, Takeshita E, Hara Y, Saraya Y, Tansho R, Shirai T, Noda K. SU-F-J-190: Time Resolved Range Measurement System Using Scintillator and CCD Camera for the Slow Beam Extraction. Med Phys 2016. [DOI: 10.1118/1.4956098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
35
|
Takata M, Tsunoda S, Ogita C, Yokoyama Y, Abe T, Maruoka M, Furukawa T, Yoshikawa T, Tanaka K, Saitou A, Nishioka A, Sekiguti M, Azuma N, Kitano M, Matsui K, Shimizu E, Sano H. AB0365 The Efficacy and Safety of Abatacept as A First Biologics in Japanese Rheumatoid Arthritis Patients Complicated by Pulmonary Involvement. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
36
|
Sawamoto R, Nozaki T, Furukawa T, Tanahashi T, Morita C, Hata T, Nakashima M, Komaki G, Sudo N. A change in objective sleep duration is associated with a change in the serum adiponectin level of women with overweight or obesity undergoing weight loss intervention. Obes Sci Pract 2016; 2:180-188. [PMID: 27812383 PMCID: PMC5069573 DOI: 10.1002/osp4.32] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 12/08/2015] [Accepted: 12/16/2015] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Although the serum adiponectin level is inversely correlated to body mass index and closely associated with obesity and related diseases, neither the impact of weight loss on the adiponectin level nor other factors that might influence the adiponectin level during weight loss intervention are well documented. OBJECTIVE The objective of the study is to assess the change in the serum adiponectin level during weight loss intervention and to determine if sleep parameters affect the serum adiponectin level. METHODS Ninety women with overweight or obesity aged 25 to 65 years completed a 7-month cognitive behavioural therapy based weight loss intervention that included dieting, exercise and stress management. Serum adiponectin level, body fat percent, symptoms of depression and anxiety and objective sleep parameters, assessed by actigraphy, were measured at baseline and at the end of the intervention. RESULTS The serum adiponectin level was significantly increased after the weight loss intervention (P < 0.001). In a multiple regression analysis, the change of the adiponectin level was positively associated with the magnitude of body fat loss (β = -0.317, P < 0.001) and an increase of sleep minutes (β = 0.210, P = 0.043). CONCLUSION An increase in objective sleep duration was related to a significantly increased serum adiponectin level independently of the change of body fat during the weight loss intervention.
Collapse
Affiliation(s)
- R Sawamoto
- Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
| | - T Nozaki
- Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
| | - T Furukawa
- Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
| | - T Tanahashi
- Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
| | - C Morita
- Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
| | - T Hata
- Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
| | - M Nakashima
- Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
| | - G Komaki
- School of Health Sciences Fukuoka International University of Health and Welfare Fukuoka Japan
| | - N Sudo
- Department of Psychosomatic Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
| |
Collapse
|
37
|
Fukushima S, Furukawa T, Niioka H, Ichimiya M, Sannomiya T, Tanaka N, Onoshima D, Yukawa H, Baba Y, Ashida M, Miyake J, Araki T, Hashimoto M. Correlative near-infrared light and cathodoluminescence microscopy using Y2O3:Ln, Yb (Ln = Tm, Er) nanophosphors for multiscale, multicolour bioimaging. Sci Rep 2016; 6:25950. [PMID: 27185264 PMCID: PMC4869039 DOI: 10.1038/srep25950] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 04/20/2016] [Indexed: 12/15/2022] Open
Abstract
This paper presents a new correlative bioimaging technique using Y2O3:Tm, Yb and Y2O3:Er, Yb nanophosphors (NPs) as imaging probes that emit luminescence excited by both near-infrared (NIR) light and an electron beam. Under 980 nm NIR light irradiation, the Y2O3:Tm, Yb and Y2O3:Er, Yb NPs emitted NIR luminescence (NIRL) around 810 nm and 1530 nm, respectively, and cathodoluminescence at 455 nm and 660 nm under excitation of accelerated electrons, respectively. Multimodalities of the NPs were confirmed in correlative NIRL/CL imaging and their locations were visualized at the same observation area in both NIRL and CL images. Using CL microscopy, the NPs were visualized at the single-particle level and with multicolour. Multiscale NIRL/CL bioimaging was demonstrated through in vivo and in vitro NIRL deep-tissue observations, cellular NIRL imaging, and high-spatial resolution CL imaging of the NPs inside cells. The location of a cell sheet transplanted onto the back muscle fascia of a hairy rat was visualized through NIRL imaging of the Y2O3:Er, Yb NPs. Accurate positions of cells through the thickness (1.5 mm) of a tissue phantom were detected by NIRL from the Y2O3:Tm, Yb NPs. Further, locations of the two types of NPs inside cells were observed using CL microscopy.
Collapse
Affiliation(s)
- S Fukushima
- Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama-cho, Toyonaka, Osaka 560-8531, Japan
| | - T Furukawa
- Institute for NanoScience Design, Osaka University, 1-3 Machikaneyama-cho, Toyonaka, Osaka 560-8531, Japan
| | - H Niioka
- Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama-cho, Toyonaka, Osaka 560-8531, Japan
| | - M Ichimiya
- Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama-cho, Toyonaka, Osaka 560-8531, Japan.,School of Engineering, The University of Shiga Prefecture, 2500 Hassaka-cho, Hikone, Shiga 522-8533, Japan
| | - T Sannomiya
- Department of Innovative and Engineered Materials, Tokyo Institute of Technology, 4259 Nagatsuta, Yokohama, Kanagawa 226-8503, Japan
| | - N Tanaka
- Quantitative Biology Center (QBiC), RIKEN, 1-3 Yamadaoka, Suita, Osaka 565-0874, Japan
| | - D Onoshima
- Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan.,ImPACT Research Center for Advanced Nanobiodevices, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan
| | - H Yukawa
- ImPACT Research Center for Advanced Nanobiodevices, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan.,Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan
| | - Y Baba
- Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan.,ImPACT Research Center for Advanced Nanobiodevices, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan.,Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan.,Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14, Hayashi-cho, Taka matsu 761-0395, Japan
| | - M Ashida
- Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama-cho, Toyonaka, Osaka 560-8531, Japan
| | - J Miyake
- Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama-cho, Toyonaka, Osaka 560-8531, Japan
| | - T Araki
- Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama-cho, Toyonaka, Osaka 560-8531, Japan
| | - M Hashimoto
- Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyama-cho, Toyonaka, Osaka 560-8531, Japan
| |
Collapse
|
38
|
Shibasaki Y, Katagiri T, Kobayashi H, Ushiki T, Narita M, Sone H, Furukawa T, Masuko M. The Dinakara equation for adjusting DLCO for hemoglobin in the HCT-CI is superior to the Cotes equation for predicting high-risk patients in allogeneic hematopoietic stem cell transplantation. Am J Hematol 2016; 91:E296. [PMID: 26840242 DOI: 10.1002/ajh.24318] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Accepted: 01/20/2016] [Indexed: 11/08/2022]
Affiliation(s)
- Yasuhiko Shibasaki
- Department of Stem Cell Transplantation; Niigata University Medical and Dental Hospital; Niigata Japan
| | - Takayuki Katagiri
- Department of Hematology, Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata Japan
| | - Hironori Kobayashi
- Department of Hematology, Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata Japan
| | - Takashi Ushiki
- Department of Hematology, Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata Japan
| | - Miwako Narita
- Department of Hematology, Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata Japan
| | - Hirohito Sone
- Department of Hematology, Endocrinology and Metabolism; Niigata University Faculty of Medicine; Niigata Japan
| | - Tatsuo Furukawa
- Department of Hematology; Nagaoka Red Cross Hospital; Niigata Japan
| | - Masayoshi Masuko
- Department of Stem Cell Transplantation; Niigata University Medical and Dental Hospital; Niigata Japan
| |
Collapse
|
39
|
Ohara N, Kaneko M, Furukawa T, Koike T, Sone H, Tanaka S, Kaneko K, Kamoi K. Rapid Normalization of High Glutamic Acid Decarboxylase Autoantibody Titers and Preserved Endogenous Insulin Secretion in a Patient with Diabetes Mellitus: A Case Report and Literature Review. Intern Med 2016; 55:485-9. [PMID: 26935368 DOI: 10.2169/internalmedicine.55.5398] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 59-year-old Japanese woman developed diabetes mellitus without ketoacidosis in the presence of glutamic acid decarboxylase autoantibody (GADA) (24.7 U/mL). After the amelioration of her hyperglycemia, the patient had a relatively preserved serum C-peptide level. Her endogenous insulin secretion capacity remained almost unchanged during 5 years of insulin therapy. The patient's GADA titers normalized within 15 months. The islet-related autoantibodies, including GADA, are believed to be produced following the autoimmune destruction of pancreatic beta cells and are predictive markers of type 1 diabetes mellitus. Therefore, the transient appearance of GADA in our patient may have reflected pancreatic autoimmune processes that terminated without progression to insulin deficiency.
Collapse
Affiliation(s)
- Nobumasa Ohara
- Department of Endocrinology and Metabolism, Nagaoka Red Cross Hospital, Japan
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Ohara N, Kaneko M, Nishibori T, Sato K, Furukawa T, Koike T, Sone H, Kaneko K, Kamoi K. Fulminant Type 1 Diabetes Mellitus Associated with Coxsackie Virus Type A2 Infection: A Case Report and Literature Review. Intern Med 2016; 55:643-6. [PMID: 26984083 DOI: 10.2169/internalmedicine.55.5292] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 65-year-old Japanese man presented to our hospital in June 2013 with a 6-day history of fever and fatigue, a 24-h history of thirst, and polyuria. His temperature was 37.8°C and he was alert. However, laboratory tests revealed severe hyperglycemia, undetectable C-peptide levels, and diabetic ketoacidosis. Serum antibody testing confirmed a Coxsackie virus A2 infection. A variety of viral infections are reported to be involved in the development of fulminant type 1 diabetes mellitus (FT1D). Our patient is the first reported case of FT1D associated with Coxsackie virus A2 infection and supports the etiological role of common viral infections in FT1D.
Collapse
Affiliation(s)
- Nobumasa Ohara
- Department of Endocrinology and Metabolism, Nagaoka Red Cross Hospital, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Hashimoto S, Kuroha T, Yano T, Sato N, Furukawa T. The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma. Intern Med 2016; 55:3025-3028. [PMID: 27746443 PMCID: PMC5109573 DOI: 10.2169/internalmedicine.55.6470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomide, and dexamethasone, adding bortezomib after starting the three-drug combination therapy. This patient has remained in a stable disease state since the beginning of this therapy. Regarding the other four cases, a partial response and a prolonged survival for approximately one year were noted. Peripheral neuropathy did not increase after thalidomide addition. Adding low-dose thalidomide may safely improve the responses for multiple myeloma refractory to bortezomib and dexamethasone.
Collapse
|
42
|
Vassiliadis A, Zanoni A, Di Leo A, Zanella S, Lauro E, Moscatelli P, Ricci F, Huang H, Wada N, Furukawa T, Kitagawa Y, Hirukawa H, Takesue Y, Saito K, Sato H, Tada T, Choua O, Fu XJ, Yao QY, Yang S, Wang MG, Zhu YL, Cao JX, Shen YM, Togbe JO, Gbessi DG, Dossou FM, Iawani I, Cijan V, Gencic M, Scepanovic M, Bojovic P, Brankovic M, Agresta F, Verza LA, Prando D, Roveran MA, Azabdaftari A, Rubinato L, Vacca U, Lubrano T, Vidotto C, Falcone A, Grasso L, Ghiglione F, Morino M, Nácul M, Cavazzola L, Loureiro M, Bonin E, Ferreira P, Misra MC, Bansal VK, Subodh K, Krisha A, Bansal D, Ray S, Rajeshwari S, Wang P, Jia Z, Zhang FJ, Yan JJ, Zhu YH, Jiang K, Altinli E, Eroglu E, Sertel HI, Hizli F, Jacob B, Bresnaham E, Reiner M, Bates A. Inguinal Hernia: Lap vs Open. Hernia 2015; 19 Suppl 1:S57-62. [PMID: 26518862 DOI: 10.1007/bf03355327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- A Vassiliadis
- Ospedale S. Maria del Carmine, UO Chirurgia, Rovereto, Italy
| | - A Zanoni
- Ospedale S. Maria del Carmine, UO Chirurgia, Rovereto, Italy
| | - A Di Leo
- Ospedale S. Maria del Carmine, UO Chirurgia, Rovereto, Italy
| | - S Zanella
- Ospedale S. Maria del Carmine, UO Chirurgia, Rovereto, Italy
| | - E Lauro
- Ospedale S. Maria del Carmine, UO Chirurgia, Rovereto, Italy
| | - P Moscatelli
- Ospedale S. Maria del Carmine, UO Chirurgia, Rovereto, Italy
| | - F Ricci
- Ospedale S. Maria del Carmine, UO Chirurgia, Rovereto, Italy
| | - H Huang
- Union Hospital, Fujian Medical University, Fuzhou, China
| | - N Wada
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - T Furukawa
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - Y Kitagawa
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - H Hirukawa
- Tachikawa General Hospital, Nagaoka, Japan
| | - Y Takesue
- Tachikawa General Hospital, Nagaoka, Japan
| | - K Saito
- Tachikawa General Hospital, Nagaoka, Japan
| | - H Sato
- Tachikawa General Hospital, Nagaoka, Japan
| | - T Tada
- Tachikawa General Hospital, Nagaoka, Japan
| | - O Choua
- N'Djaména School of Medecine, N'Djaména, Chad
| | | | - Q Y Yao
- Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
| | | | - M G Wang
- Department of Hernia and Abdominal Wall Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | | | | | | | | | | | | | | | - V Cijan
- Surgery department, Clinical Hospital Center Zvezdara, Belgrade, Serbia
| | | | | | | | | | - F Agresta
- Dept. of General Surgery, ULSS19 del Veneto, Adria, RO, Italy
| | - L A Verza
- Dept. of General Surgery, ULSS19 del Veneto, Adria, RO, Italy
| | - D Prando
- Dept. of General Surgery, ULSS19 del Veneto, Adria, RO, Italy
| | - M A Roveran
- Dept. of General Surgery, ULSS19 del Veneto, Adria, RO, Italy
| | - A Azabdaftari
- Dept. of General Surgery, ULSS19 del Veneto, Adria, RO, Italy
| | - L Rubinato
- Dept. of General Surgery, ULSS19 del Veneto, Adria, RO, Italy
| | - U Vacca
- Dept. of General Surgery, ULSS19 del Veneto, Adria, RO, Italy
| | - T Lubrano
- Azienda Ospedaliera Città della Salute e della Scienza, SCDU Chirurgia Generale I, Università degli Studi di Torino, Torino, Italy
| | - C Vidotto
- Azienda Ospedaliera Città della Salute e della Scienza, SCDU Chirurgia Generale I, Università degli Studi di Torino, Torino, Italy
| | - A Falcone
- Azienda Ospedaliera Città della Salute e della Scienza, SCDU Chirurgia Generale I, Università degli Studi di Torino, Torino, Italy
| | - L Grasso
- Azienda Ospedaliera Città della Salute e della Scienza, SCDU Chirurgia Generale I, Università degli Studi di Torino, Torino, Italy
| | - F Ghiglione
- Azienda Ospedaliera Città della Salute e della Scienza, SCDU Chirurgia Generale I, Università degli Studi di Torino, Torino, Italy
| | - M Morino
- Azienda Ospedaliera Città della Salute e della Scienza, SCDU Chirurgia Generale I, Università degli Studi di Torino, Torino, Italy
| | - M Nácul
- Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - L Cavazzola
- Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | | | - E Bonin
- Universidade Positivo, Curitiba, Brazil
| | | | - M C Misra
- All India Institute of Medical Sciences, New Delhi, India
| | - V K Bansal
- All India Institute of Medical Sciences, New Delhi, India
| | | | | | | | | | | | - P Wang
- Center of Hernia Surgery Department of Nanjing Medical, University associated HangZhou Hospital, Hangzhou, China
| | | | | | | | | | | | - E Altinli
- Dept. of General Surgery, TC Istanbul Bilim University, Istanbul, Turkey
| | - E Eroglu
- Dept. of General Surgery, TC Istanbul Bilim University, Istanbul, Turkey
| | - H I Sertel
- Florence Nightingale Kadikoy Hospital, Istanbul, Turkey
| | - F Hizli
- Florence Nightingale Kadikoy Hospital, Istanbul, Turkey
| | - B Jacob
- Mount Sinai Medical Center, New York, USA
| | | | | | | |
Collapse
|
43
|
Kondo H, Kanemura T, Furukawa T, Hirakawa Y, Wakai E, Groeschel F, Nitti F, Knaster J. Validation of IFMIF liquid Li target for IFMIF/EVEDA project. Fusion Engineering and Design 2015. [DOI: 10.1016/j.fusengdes.2015.01.036] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
44
|
Nishiguchi K, Yokoyama Y, Fujii Y, Furukawa T, Ono F, Shimozawa N, Togo M, Suzuki M, Nakazawa T. Association between drusen and blood test results in a colony of 1,174 monkeys. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0317] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- K. Nishiguchi
- Department of Advanced Ophthalmic Medicine; Tohoku University Graduate School of Medicine; Sendai Japan
| | - Y. Yokoyama
- Department of Ophthalmology; Tohoku University Graduate School of Medicine; Sendai Japan
| | - Y. Fujii
- Department of Ophthalmology; Tohoku University Graduate School of Medicine; Sendai Japan
| | - T. Furukawa
- Department of Comparative Animal Science; Kurashiki University of Science and the Arts; Kurashiki Japan
| | - F. Ono
- Faculty of Risk and Crisis Management; Chiba Institute of Science; Choshi Japan
| | - N. Shimozawa
- National Institute of Biomedical Innovation- Health and Nutrition; Tsukuba Primate Research Center; Tsukuba Japan
| | - M. Togo
- The Corporation for Production and Research of Laboratory Primates; Tsukuba Japan
| | - M. Suzuki
- The Corporation for Production and Research of Laboratory Primates; Tsukuba Japan
| | - T. Nakazawa
- Department of Ophthalmology; Tohoku University Graduate School of Medicine; Sendai Japan
| |
Collapse
|
45
|
Hamai Y, Hihara J, Furukawa T, Yamakita I, Kurokawa T, Okada M. 2225 Prediction of tumor response and survival using 18F-fluorodeoxyglucose PET in trimodality therapy for esophageal squamous cell carcinoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31141-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
46
|
Furukawa T, Miyagawa K, Itou T, Ito M, Taniguchi H, Saito M, Iguchi S, Sasaki T, Kanoda K. Quantum Spin Liquid Emerging from Antiferromagnetic Order by Introducing Disorder. Phys Rev Lett 2015; 115:077001. [PMID: 26317741 DOI: 10.1103/physrevlett.115.077001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Indexed: 06/04/2023]
Abstract
Quantum spin liquids, which are spin versions of quantum matter, have been sought after in systems with geometrical frustration. We show that disorder drives a classical magnet into a quantum spin liquid through conducting NMR experiments on an organic Mott insulator, κ-(ET)_{2}Cu[N(CN)_{2}]Cl. Antiferromagnetic ordering in the pristine crystal, when irradiated by x rays, disappears. Spin freezing, spin gap, and critical slowing down are not observed, but gapless spin excitations emerge, suggesting a novel role of disorder that brings forth a quantum spin liquid from a classical ordered state.
Collapse
Affiliation(s)
- T Furukawa
- Department of Applied Physics, University of Tokyo, Tokyo 113-8656, Japan
| | - K Miyagawa
- Department of Applied Physics, University of Tokyo, Tokyo 113-8656, Japan
| | - T Itou
- Department of Applied Physics, Tokyo University of Science, Tokyo 125-8585, Japan
| | - M Ito
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - H Taniguchi
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - M Saito
- Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan
| | - S Iguchi
- Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan
| | - T Sasaki
- Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan
| | - K Kanoda
- Department of Applied Physics, University of Tokyo, Tokyo 113-8656, Japan
| |
Collapse
|
47
|
Saotome N, Hara Y, Tansho R, Saraya Y, Mizushima K, Furukawa T, Shirai T, Noda K. TH-CD-BRA-07: Range Verification System Using Scintillator and CCD Camera for the Scanning Irradiation System. Med Phys 2015. [DOI: 10.1118/1.4926232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
48
|
Kitano M, Kitano S, Sekiguchi M, Azuma N, Abe T, Ogita C, Yokoyama Y, Yoshikawa T, Furukawa T, Hino T, Saito A, Nishioka A, Tsunoda S, Hashimoto N, Matsui K, Iwasaki T, Sano H. SAT0158 Comparison of Early Effect on Bone Metabolism in Patients with Active Rheumatoid Arthritis After Tocilizumab or Abatacept Therapy: Results from Propensity Score Analysis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Furukawa T, Takasugi S, Kato T, Urakabe S, Inoue M. Prediction of the effect of corticosteroid on idiopathic nephrotic syndrome based on a discriminant function. Contrib Nephrol 2015; 6:61-72. [PMID: 856537 DOI: 10.1159/000399753] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
For the purpose of discriminating between cases of nephrotic syndrome with and without corticosteroid effect, a linear discriminant function was applied in attempt to predict the effect of corticosteroid by the use of a computer. The parameters used were 15-min values of the PSP test, urinary protein, serum cholesterol, renal biospy findings, the number of red cells in the urinary sediment and immunoglobulin clearance ratio. The rate of correct prediction using the function with immunoglobulin clearance ratio was 87.0 %.
Collapse
|
50
|
Sakamoto Y, Bidinosti CP, Ichikawa Y, Sato T, Ohtomo Y, Kojima S, Funayama C, Suzuki T, Tsuchiya M, Furukawa T, Yoshimi A, Ino T, Ueno H, Matsuo Y, Fukuyama T, Asahi K. Development of high-homogeneity magnetic field coil for 129Xe EDM experiment. ACTA ACUST UNITED AC 2015. [DOI: 10.1007/s10751-014-1109-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|